Safety and feasibility of TCM-derived CD19 CART-cell therapy was demonstrated for treatment of poor-risk NHL patients undergoing autologous HSCT (hematopoietic stem cell transplantation) (50). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.